Participated · Seed · Jan 2026

Nanochon is building Chondrograft™, a patented implant designed to restore articular cartilage in the knee while allowing immediate weight-bearing and motion. The technology targets young, active patients who have failed conservative therapies and currently face costly, invasive, and often short-lived treatment options. The company is about to launch a 10-patient, phase-I first-in-human clinical study in Canada to assess Chondrograft’s safety and efficacy, and is already planning a larger North American pivotal trial aimed at eventual FDA clearance. Beyond the implant, Nanochon has partnered with ProVoyance to create an MRI-based pre-operative surgical-planning software platform. The newly raised capital will also accelerate manufacturing capabilities and deepen R&D. Including the latest round, Nanochon has secured a total of $11.3 million in funding to date, underscoring strong investor confidence in its approach.

Participated · Series C · Dec 2022

BrightSpec commercializes MRR, a novel spectroscopic technique that rapidly and definitively characterizes the unique three-dimensional structures of small molecules, including structural, spatial, and isotopic isomers. MRR leverages computational quantum chemistry to predict and validate structures without the need for reference standards. The company maintains an extensive database of calculated and validated structural spectra and offers tools for rapid identification of unknown compounds in crude samples. Its workflow enables high-throughput analysis without chromatography, providing quantitation directly from crude mixtures in minutes, and can be paired with software and minimal sample prep to deploy targeted instruments outside of analytical labs. BrightSpec reports customers across the pharmaceutical, consumer and beverage, and industrial chemical industries. The company intends to use the Series C proceeds to expand development efforts and broaden its business reach.

Participated · Series A · Jul 2022

Astraea offers EarthAI, a software-as-a-service platform that leverages geospatial data from more than 1,000 satellites. The platform uses artificial intelligence, machine learning, and cloud computing to generate operational satellite insights. Astraea serves multiple industries, including clean energy, agriculture, conservation, carbon finance, and real estate. The company plans to use new funding to support business development, hire data scientists, and expand commercial partnerships with satellite data providers. Astraea is led by CEO Brendan Richardson and is based in Charlottesville, VA. The company recently completed a Series A financing to advance its commercial growth.

Participated · Seed · Mar 2021

Babylon Micro-Farms produces the Galleri, a large $15,000 wall appliance that can grow more than 50 plant varieties and—on its own—produce up to 24 pounds of leafy greens per month. The company pairs the hardware with BabylonIQ, a proprietary platform that automatically controls growing conditions, schedules planting and harvesting, reorders supplies, and provides real-time plant-health analysis and predictive maintenance for distributed fleets. Babylon is focused on food-service verticals such as healthcare, education and corporate customers, and also offers a hardware-as-a-service subscription option for buyers who do not want to purchase a system outright. The startup is based in Richmond, Virginia, manufactures the Galleri locally, and operates with a lean team of 35. The company announced an $8 million Series A and said the funds will accelerate production, marketing and expansion of its install base. Babylon also received a $500,000 National Science Foundation grant and previously raised roughly $3 million in a seed round almost two years earlier. Babylon Micro-Farms offers a cloud-based, plug-and-play hydroponics system for indoor farming operations. The company’s 15-square-foot miniature farms can, the company says, grow as much produce as 2,000 square feet of outdoor cropland and are remotely managed via a platform that controls light, water, and nutrients. Babylon deploys a fleet of remotely managed vertical farms and offers two-year lease contracts so users can test markets without long-term commitments. The startup plans to use the new capital to fund nationwide expansion and accelerate market penetration through national distribution. Financially, Babylon raised an initial $2.3 million seed in January 2020 led by CIT GAP Funds and Plug and Play Ventures and has now closed an additional $3.0 million seed round. CEO Alexander Olesen said 2021 is on track for accelerating growth as the company focuses on deploying its indoor farming service. Babylon Micro-Farms offers a 32” x 66” x 96” plug-and-play hydroponics machine paired with cloud-based software that remotely manages nutrients, irrigation, and LED lighting. The system supports 227 seed varieties and automatically dispenses water, nutrients, and light while collecting growth data to optimize performance and reduce labor costs. The company leases machines on two-year contracts with fixed monthly fees, handling installation and supplying growing inputs. Babylon claims each 15 square-foot micro-farm can produce as much as 2,000 square feet of outdoor farmland. To date it has focused on product development and pilot deployments with customers including UVA, Dominion Energy, local restaurants, schools, and country clubs. Co-founders Alexander Olesen and Grant Smith plan regional expansion, expecting thousands of installations across North America within five years and sales outside Virginia beginning early next year.

Participated · Series A · Jun 2019

RxRevu is a Denver, CO–based prescription decision-support company led by CEO Carm Huntress. Its core product, SwiftRx, brings patient-specific data from pharmacy benefit managers (PBMs) into electronic health records (EHRs), displaying accurate, real-time coverage and benefit details. The platform helps providers prescribe lower-cost medication options and reduces prior authorization volumes and downstream administrative work. The company said the new funding will be used to develop the SwiftRx platform and to expand personnel and technical capabilities. RxRevu closed a $7M Series B that brought total investment in the company to $28M. The financing was led by JAZZ Venture Partners with additional investments from existing strategic health system partners. RxRevu provides a platform and a suite of Prescription Decision Support tools that help healthcare professionals make more informed prescribing decisions. Its tools consider a patient’s medical history, individual insurance coverage and the out-of-pocket cost patients will pay at their preferred pharmacy. The platform also enables health systems to holistically manage and measure clinicians’ prescribing performance. The company is led by co-founder and CEO Carm Huntress and is based in Denver, Colorado. RxRevu raised $15.9M in a Series A round and intends to use the funds for continued growth. In conjunction with the funding, Toby Cosgrove, M.D. and Richard Zane, M.D. joined the RxRevu board of directors. RxREVU provides medication cost and quality prescription optimization solutions that help patients and payers identify cost-saving opportunities on prescription drugs. The company offers its solutions through web and mobile consumer applications. Its healthcare customers include health plans, employer groups and population health organizations. RxREVU is led by CEO Carm Huntress and Chief Medical Officer Kevin O’Brien, M.D. The company is a member of the StartUp Health Academy and has announced partnerships with Yingo Yango, Medullan and Medical Home Exchange. Those partnerships deliver patient-engagement solutions to millions of combined users.